Conference reports

HSV-2 suppression reduces HIV and HSV shedding

13th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 February 2006, Denver

Early integrase inhibitor studies in treatment experienced patients raise hopes for new drugs in a new class

Atazanavir in treatment naive patients, with and without ritonavir boosting

Simplification to atazanavir/ritonavir monotherapy

Summary of STI studies: SMART shows clear increased risk from interrupting treatment at any CD4 count

The effect of repeated single-dose nevirapine for PMTCT in a second pregnancy

Should criteria for initiation of HAART be revisited in pregnant women?

Cotrimoxazole prophylaxis in pregnancy

Treatment in primary HIV infection

CNS penetration of ARV drugs is associated with lower CSF viral load

Sexual transmission of hepatitis C in HIV-positive men in the UK

D:A:D study shows that PIs rather than NNRTIs drive the previously reported cardiovascular risk of combination antiretroviral therapy

Interventions for the management of lipodystrophy and metabolic complications

45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 16-19 December 2005, Washington, USA

One third of HIV/HCV coinfected patients with normal ALT have advanced fibrosis in Spanish cohort

10th European AIDS Conference (EACS), 17-20 November 2005, Dublin, Ireland

Rifaximin cure reported for cryptosporidium in advanced HIV

Analysis of hepatic events in 2NN study by CD4 entry criteria, levels differences between nevirapine and efavirenz; excess hepatic events in once-daily nevirapine arm linked to single site in Thailand

FTC studies at EACS: reduced incidence of M184V compared to 3TC; side effect profile in clinical practice

Paediatric studies at EACS: trends in antiretroviral use in the Madrid Cohort; life expectancy significantly increased HIV/HCV co-infected children since HAART; use of tenofovir in treatment experienced children; switching to lopinavir/r from double protease inhibitor regimen; once daily lopinavir/r, 3TC and abacavir; planned treatment interruptions in children

Efficacy of lopinavir/r in patients with advanced HIV (CD4 <25 cells/mm3)

Potential barriers to use of T-20: results from patient and physician interviews

Factors associated with sexual dysfunction in HIV patients

Decreased varicella zoster immunity in migrants from sub-Saharan Africa

Clinical experience of switching to atazanavir in the UK’s largest clinic

Replacing a PI with atazanavir: separating swans from ducklings?

TMC 125: some good and bad news

When to change a failing regimen: second-line and salvage strategies

Antiretrovirals and other stuff!

Heart disease in people with HIV

Mortality trends: why people with HIV die (or don’t) today

45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 16-19 December 2005, Washington, USA

Understanding TMC114 power against resistant HIV

New antiretroviral compounds at ICAAC: new PI brecanavir from GSK; maturation inhibitor PA-457; antiviral activity of monoclonal antibody; TNX-355 in treatment experienced patients

Comparison of pharmacokinetics of originator and generic liquid formulations and split tablets in Malawian children

African-Americans in ACTG 5095 had shorter time to virologic failure and grade 3/4 side effects

Predictors of insulin resistance in first year of therapy

Three measures confirm 144-week renal record of tenofovir

Low rash risk with efavirenz after nevirapine rash

7th Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 13-16 November 2005, Dublin, Ireland

Monitoring side effects in resource limited countries

Uridine supplement reverses thymidine-induced lipoatrophy

Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia

Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir

Niacin has beneficial effect on lipids but no reduction in abdominal fat

Gluteal implants used to replace lost buttock fat

10th European AIDS Conference, 17-20 November 2005, Dublin, Ireland

Pregnancy studies at EACS

Further Reports from 3rd IAS Conference on AIDS Pathogenesis and Treatment, Rio de Janeiro, Brazil, 24-27 July 2005

Management of hepatitis C and B in HIV-coinfected individuals: an overview of studies presented at the 3rd IAS Conference

Highlights of HIV drug resistance studies presented at the 3rd IAS Conference

3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil

Adult male circumcision reduces transmission rates over 18 months comparable to a vaccine with 65% efficacy

Benefits of adding 4 or 7 days of AZT/3TC to single-dose nevirapine to prevent MTCT: further analysis from TOPS

New drugs in pregnancy: atazanavir; T20

Lopinavir/r use in children less than two years old – promising results despite low plasma levels

Favourable outcomes in children treated with HAART in the MSF programmes

Encouraging results with cut up generic fixed dose combination tablets in Uganda

Predictors of survival at three years follow up for HIV-infected children in Cote D’Ivoire

Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results

T20 (enfuvirtide) studies presented at Rio

Strategies for salvage therapy

Antiviral activity of foscarnet in salvage patients

Novel strategies with existing drugs

Post navigation